vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Oportun Financial Corp (OPRT). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $247.7M, roughly 1.1× Oportun Financial Corp). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 1.4%, a 95.0% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -1.3%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -0.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Oportun Financial Corp is a US-based fintech firm that provides accessible, responsible financial services including personal loans, credit cards, and savings products to underserved low-to-moderate income consumers, many with limited or no credit history, leveraging proprietary AI underwriting to deliver fair terms while mitigating operational risk.
ACAD vs OPRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $247.7M |
| Net Profit | $273.6M | $3.4M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 2.6% |
| Net Margin | 96.3% | 1.4% |
| Revenue YoY | 9.4% | -1.3% |
| Net Profit YoY | 90.3% | -61.0% |
| EPS (diluted) | $1.61 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $247.7M | ||
| Q3 25 | $278.6M | $238.7M | ||
| Q2 25 | $264.6M | $234.3M | ||
| Q1 25 | $244.3M | $235.9M | ||
| Q4 24 | $259.6M | $250.9M | ||
| Q3 24 | $250.4M | $250.0M | ||
| Q2 24 | $242.0M | $250.4M | ||
| Q1 24 | $205.8M | $250.5M |
| Q4 25 | $273.6M | $3.4M | ||
| Q3 25 | $71.8M | $5.2M | ||
| Q2 25 | $26.7M | $6.9M | ||
| Q1 25 | $19.0M | $9.8M | ||
| Q4 24 | $143.7M | $8.7M | ||
| Q3 24 | $32.8M | $-30.0M | ||
| Q2 24 | $33.4M | $-31.0M | ||
| Q1 24 | $16.6M | $-26.4M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 2.6% | ||
| Q3 25 | 12.8% | 6.0% | ||
| Q2 25 | 12.2% | 4.3% | ||
| Q1 25 | 7.9% | 5.6% | ||
| Q4 24 | 59.1% | 89.6% | ||
| Q3 24 | 12.6% | -15.8% | ||
| Q2 24 | 12.6% | -19.6% | ||
| Q1 24 | 7.4% | -12.2% |
| Q4 25 | 96.3% | 1.4% | ||
| Q3 25 | 25.8% | 2.2% | ||
| Q2 25 | 10.1% | 2.9% | ||
| Q1 25 | 7.8% | 4.1% | ||
| Q4 24 | 55.4% | 200.1% | ||
| Q3 24 | 13.1% | -12.0% | ||
| Q2 24 | 13.8% | -12.4% | ||
| Q1 24 | 8.0% | -10.6% |
| Q4 25 | $1.61 | $0.07 | ||
| Q3 25 | $0.42 | $0.11 | ||
| Q2 25 | $0.16 | $0.14 | ||
| Q1 25 | $0.11 | $0.21 | ||
| Q4 24 | $0.86 | $0.26 | ||
| Q3 24 | $0.20 | $-0.75 | ||
| Q2 24 | $0.20 | $-0.78 | ||
| Q1 24 | $0.10 | $-0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $105.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $390.1M |
| Total Assets | $1.6B | $3.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $105.5M | ||
| Q3 25 | $258.0M | $104.6M | ||
| Q2 25 | $253.6M | $96.8M | ||
| Q1 25 | $217.7M | $78.5M | ||
| Q4 24 | $319.6M | $60.0M | ||
| Q3 24 | $155.1M | $71.8M | ||
| Q2 24 | $177.1M | $72.9M | ||
| Q1 24 | $204.7M | $69.2M |
| Q4 25 | $1.2B | $390.1M | ||
| Q3 25 | $917.3M | $383.9M | ||
| Q2 25 | $822.4M | $376.0M | ||
| Q1 25 | $765.2M | $366.1M | ||
| Q4 24 | $732.8M | $353.8M | ||
| Q3 24 | $577.2M | $327.6M | ||
| Q2 24 | $516.7M | $354.1M | ||
| Q1 24 | $464.0M | $382.0M |
| Q4 25 | $1.6B | $3.3B | ||
| Q3 25 | $1.3B | $3.2B | ||
| Q2 25 | $1.2B | $3.2B | ||
| Q1 25 | $1.1B | $3.2B | ||
| Q4 24 | $1.2B | $3.2B | ||
| Q3 24 | $976.9M | $3.3B | ||
| Q2 24 | $914.1M | $3.3B | ||
| Q1 24 | $855.1M | $3.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $413.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | 121.45× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $413.4M | ||
| Q3 25 | $74.3M | $99.0M | ||
| Q2 25 | $64.0M | $104.5M | ||
| Q1 25 | $20.3M | $101.0M | ||
| Q4 24 | $40.4M | $393.5M | ||
| Q3 24 | $63.2M | $108.5M | ||
| Q2 24 | $25.0M | $107.7M | ||
| Q1 24 | $29.1M | $85.9M |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -0.18× | 121.45× | ||
| Q3 25 | 1.03× | 19.05× | ||
| Q2 25 | 2.40× | 15.20× | ||
| Q1 25 | 1.07× | 10.34× | ||
| Q4 24 | 0.28× | 45.04× | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
OPRT
Segment breakdown not available.
